{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:23:54Z","timestamp":1770881034788,"version":"3.50.1"},"publisher-location":"Chichester, UK","reference-count":94,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd003370.pub2","type":"reference-entry","created":{"date-parts":[[2007,1,25]],"date-time":"2007-01-25T08:35:23Z","timestamp":1169714123000},"source":"Crossref","is-referenced-by-count":28,"title":["Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women"],"prefix":"10.1002","author":[{"given":"Lorna","family":"Gibson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Bliss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,1,24]]},"reference":[{"key":"10.1002\/14651858.CD003370.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1159\/000226639","article-title":"Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer","volume":"45","author":"Alonso-Munzo","year":"1988","journal-title":"Oncology"},{"key":"10.1002\/14651858.CD003370.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1159\/000011888","article-title":"Fadrozole versus megestrol acetate: a double-blind randomised trial in advanced breast cancer","volume":"55","author":"Bezwoda","year":"1998","journal-title":"Oncology"},{"issue":"9","key":"10.1002\/14651858.CD003370.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y","article-title":"Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma","volume":"92","author":"Bonneterre","year":"2001","journal-title":"Cancer"},{"issue":"22","key":"10.1002\/14651858.CD003370.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1200\/JCO.2000.18.22.3748","article-title":"Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study","volume":"18","author":"Bonneterre","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003370.pub2-BIB7|cit5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0960-0760(03)00374-1","article-title":"Advanced breast cancer updates on anastrozole versus tamoxifen","volume":"86","author":"Nabholtz","year":"2003","journal-title":"Journal of Steroid Biochemistry and Molecular Biology"},{"key":"10.1002\/14651858.CD003370.pub2-BIB5|cit6","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0959-8049(03)00326-5","article-title":"Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results","volume":"39","author":"Nabholtz","year":"2003","journal-title":"European Journal of Cancer"},{"issue":"22","key":"10.1002\/14651858.CD003370.pub2-BIB6|cit7","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","article-title":"Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial","volume":"18","author":"Nabholtz","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003370.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/S0959-8049(03)00602-6","article-title":"Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women","volume":"39","author":"Thuerlimann","year":"2003","journal-title":"European Journal of Cancer"},{"issue":"Suppl:","key":"10.1002\/14651858.CD003370.pub2-BIB9|cit9","first-page":"81","article-title":"Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women","volume":"36","author":"Vergote","year":"2000","journal-title":"European Journal of Cancer"},{"issue":"2000 - 11","key":"10.1002\/14651858.CD003370.pub2-BIB10|cit10","article-title":"Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analsyis of two phase III trials","volume":"14","author":"Budzar","year":"1996","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD003370.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1142::AID-CNCR13>3.3.CO;2-7","article-title":"Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma","volume":"83","author":"Buzdar","year":"1998","journal-title":"Cancer"},{"issue":"3-6","key":"10.1002\/14651858.CD003370.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0960-0760(97)80006-4","article-title":"Arimidex: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer","volume":"61","author":"Buzdar","year":"1997","journal-title":"Journal Steroid Biochemistry Molecular Biology"},{"key":"10.1002\/14651858.CD003370.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3111\/199902033043","article-title":"Cost-effectiveness implications of increased survival with anastrozole in the treatment of advanced breast cancer","volume":"2","author":"Drummond","year":"1999","journal-title":"Journal of Medical Economics"},{"issue":"3","key":"10.1002\/14651858.CD003370.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/0959-8049(95)00014-3","article-title":"A randomized trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal women with advanced breast cancer","volume":"32A","author":"Jonat","year":"1996","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD003370.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1023\/A:1006391902868","article-title":"Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer","volume":"58","author":"Robertson","year":"1999","journal-title":"Breast Cancer Research and Treatment"},{"issue":"12","key":"10.1002\/14651858.CD003370.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1002\/(SICI)1097-0142(19960615)77:12<2503::AID-CNCR13>3.0.CO;2-W","article-title":"Fadrazole HCl (CGS-16949A) versus megestrol acetate in postmenopausal patients with metatatic breast carcinoma: results of two randomized, double-blind, controlled multi-institutional trials","volume":"77","author":"Buzdar","year":"1996","journal-title":"Cancer"},{"issue":"12","key":"10.1002\/14651858.CD003370.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1002\/(SICI)1097-0142(19960615)77:12<2503::AID-CNCR13>3.0.CO;2-W","article-title":"Fadrazole HCl (CGS-16949A) versus megestrol acetate in postmenopausal patients with metatatic breast carcinoma: results of two randomized, double-blind, controlled multi-institutional trials","volume":"77","author":"Buzdar","year":"1996","journal-title":"Cancer"},{"issue":"14","key":"10.1002\/14651858.CD003370.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1200\/JCO.2001.19.14.3357","article-title":"Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate","volume":"19","author":"Buzdar","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"14","key":"10.1002\/14651858.CD003370.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/jnci\/80.14.1147","article-title":"Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma","volume":"80","author":"Canney","year":"1988","journal-title":"Journal of the National Cancer Institute"},{"issue":"2","key":"10.1002\/14651858.CD003370.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.1998.16.2.453","article-title":"Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate","volume":"16","author":"Dombernowsky","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003370.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/oxfordjournals.annonc.a010634","article-title":"A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer","volume":"7","author":"Falkson","year":"1996","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD003370.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1023\/A:1008226721932","article-title":"Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer","volume":"9","author":"Gershanovich","year":"1998","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD003370.pub2-BIB23|cit23","first-page":"361","article-title":"Letrozole, a new aromatase for advanced breast cancer","volume":"4","author":"Gershanovitch","year":"45","journal-title":"Voprosy onkolgii"},{"issue":"1","key":"10.1002\/14651858.CD003370.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.1999.17.1.52","article-title":"Randomized phase III trial comparing the new potent and selective third generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients","volume":"17","author":"Goss","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD003370.pub2-BIB25|cit25","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1200\/JCO.1986.4.6.958","article-title":"Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer","volume":"4","author":"Ingle","year":"1986","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003370.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/1097-0142(20010201)91:3<484::AID-CNCR1026>3.0.CO;2-D","article-title":"Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma","volume":"91","author":"Hillner","year":"2001","journal-title":"Cancer"},{"issue":"Suppl","key":"10.1002\/14651858.CD003370.pub2-BIB27|cit27","first-page":"81","article-title":"Exemestane improves survival compared with megestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen: results of a double-blind randomised phase III trial","volume":"36","author":"Kaufmann","year":"2000","journal-title":"European Journal of Cancer"},{"issue":"7","key":"10.1002\/14651858.CD003370.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1200\/JCO.2000.18.7.1399","article-title":"Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomised double-blind trial","volume":"18","author":"Kaufmann","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003370.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000227752","article-title":"A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer","volume":"54","author":"Kleeberg","year":"1997","journal-title":"Oncology"},{"key":"10.1002\/14651858.CD003370.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1023\/A:1008308609325","article-title":"A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer","volume":"10","author":"Vorobiof","year":"1999","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD003370.pub2-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1200\/JCO.1995.13.5.1129","article-title":"Elevated Serum c-erb B-2 Antigen Levels and decreased response to hormone therapy of breast cancer","volume":"13","author":"Leitzel","year":"1995","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"10.1002\/14651858.CD003370.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2002.10.057","article-title":"Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment","volume":"20","author":"Howell","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD003370.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0959-8049(03)00199-0","article-title":"Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metasteses: combined results from two multicentre trials","volume":"39","author":"Mauriac","year":"2003","journal-title":"European Journal of Cancer"},{"issue":"16","key":"10.1002\/14651858.CD003370.pub2-BIB34|cit34","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1200\/JCO.2002.10.058","article-title":"Double-blind, randomized trial comparing the efficacy and tolerability of the fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American Trial","volume":"20","author":"Osborne","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD003370.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cncr.11468","article-title":"Fulvestrant versus Anastrozole for the treatment of advanced breast carcinoma in postmenopausal women","volume":"98","author":"Robertson","year":"2003","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD003370.pub2-BIB36|cit36","doi-asserted-by":"crossref","unstructured":"Vergote I Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women European Journal of Cancer 2002 Suppl: 57-8","DOI":"10.1016\/S0959-8049(02)00287-3"},{"key":"10.1002\/14651858.CD003370.pub2-BIB37|cit37","first-page":"254","article-title":"Trial of aminoglutethimide vs hydrocortisone as second-line hormone treatment of advanced breast cancer","volume":"19","author":"Mercer","year":"1993","journal-title":"European Journal of Surgical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003370.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/01.COC.0000047126.10522.F9","article-title":"Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer","volume":"26","author":"Milla-Santos","year":"2003","journal-title":"American Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003370.pub2-BIB39|cit39","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1634\/theoncologist.9-5-489","article-title":"Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability","volume":"9","author":"Mourisdan","year":"2004","journal-title":"The Oncologist"},{"issue":"11","key":"10.1002\/14651858.CD003370.pub2-BIB40|cit40","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2003.04.194","article-title":"Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group","volume":"21","author":"Mourisden","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD003370.pub2-BIB41|cit41","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1200\/JCO.2001.19.10.2596","article-title":"Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced brreast cancer: results of a phase III study of the international letrozole breast cancer group","volume":"19","author":"Mourisden","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD003370.pub2-BIB42|cit42","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/annonc\/mdh064","article-title":"The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a comparison study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'","volume":"15","author":"Atalay","year":"2004","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD003370.pub2-BIB43|cit43","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/annonc\/mdg362","article-title":"Mature results of a randomized phase II multicenter study of exemextane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer","volume":"14","author":"Paridaens","year":"2003","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD003370.pub2-BIB44|cit44","first-page":"Suppl 7 19-24","article-title":"Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer","volume":"5","author":"Perez Carrion","year":"1994","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD003370.pub2-BIB45|cit45","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/S0140-6736(84)91872-5","article-title":"Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially","author":"Powles","year":"1984","journal-title":"The Lancet"},{"issue":"2","key":"10.1002\/14651858.CD003370.pub2-BIB46|cit46","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1023\/A:1006460925986","article-title":"Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer","volume":"61","author":"Rose","year":"2000","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1002\/14651858.CD003370.pub2-BIB47|cit47","first-page":"Suppl 45-50","article-title":"Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomised trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone","volume":"7","author":"Rose","year":"1986","journal-title":"Breast Cancer Research and Treatment"},{"issue":"16","key":"10.1002\/14651858.CD003370.pub2-BIB48|cit48","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/S0959-8049(03)00630-0","article-title":"An open randomised trial of second-line endocrine therapy in advanced breast cancer","volume":"39","author":"Rose","year":"2003","journal-title":"European Journal of Cancer"},{"issue":"12","key":"10.1002\/14651858.CD003370.pub2-BIB49|cit49","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.ejca.2004.02.030","article-title":"An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the Aromatase inhibitors letrozole and anastrozole","volume":"40","author":"Tobias","year":"2004","journal-title":"European Journal of Cancer"},{"issue":"7","key":"10.1002\/14651858.CD003370.pub2-BIB50|cit50","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1200\/JCO.1997.15.7.2494","article-title":"Megestrol acetate and aminoglutethimide\/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a southwest oncology group phase III trial","volume":"15","author":"Russell","year":"1997","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003370.pub2-BIB51|cit51","first-page":"77","article-title":"Self organizing maps and prognosis of advanced breast cancer patients with bone metastases receiving letrozole or MA","volume":"64","author":"Schmid","year":"2001","journal-title":"Breast Cancer Research and Treament"},{"key":"10.1002\/14651858.CD003370.pub2-BIB52|cit52","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/oxfordjournals.annonc.a010635","article-title":"First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer","volume":"7","author":"Thuerlimann","year":"1996","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD003370.pub2-BIB53|cit53","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0959-8049(99)00028-3","article-title":"Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment","volume":"35","author":"Bernhard","year":"1999","journal-title":"European Journal of Cancer"},{"issue":"6","key":"10.1002\/14651858.CD003370.pub2-BIB54|cit54","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1200\/JCO.1999.17.6.1672","article-title":"Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter","volume":"17","author":"Bernhard","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD003370.pub2-BIB55|cit55","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0959-8049(97)00105-6","article-title":"Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20\/90)","volume":"33","author":"Thuerlimann","year":"1997","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD003370.pub2-BIB56|cit56","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/annonc\/mdg014","article-title":"Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer","volume":"14","author":"Tominaga","year":"2003","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD003370.pub2-BIB57|cit57","first-page":"729","article-title":"CGS20267 (letrozole), a new aromatase inhibitor: late phase II study for postmenopausal women with advanced or recurrent breast cancer (no. 1) - investigation of recommended clinical dose CGS20267 Study Group","volume":"29","author":"Abe","year":"2002","journal-title":"Gan To Kaguku Ryoho"},{"key":"10.1002\/14651858.CD003370.pub2-BIB58|cit58","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/bjc.1994.265","article-title":"Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer","volume":"70","author":"Bajetta","year":"1994","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD003370.pub2-BIB59|cit59","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF00666055","article-title":"Effect of two 4-hydroxyandrostenedione doses on serum insulin-like growth factor I levels in advanced breast cancer","volume":"30","author":"Ferrari","year":"1994","journal-title":"Breast Cancer Research and Treatment"},{"issue":"4","key":"10.1002\/14651858.CD003370.pub2-BIB60|cit60","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0959-8049(96)00494-7","article-title":"The minimal effective exemestane dose for endocrine activity in advanced breast cancer","volume":"33","author":"Bajetta","year":"1997","journal-title":"European Journal of Cancer"},{"issue":"4-6","key":"10.1002\/14651858.CD003370.pub2-BIB61|cit61","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0960-0760(97)00120-9","article-title":"The aromatase inhibitor letrozole in advanced breast cancer: effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels","volume":"63","author":"Bajetta","year":"1997","journal-title":"Journal of steroid Biochemistry"},{"issue":"2","key":"10.1002\/14651858.CD003370.pub2-BIB62|cit62","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0959-8049(98)00392-X","article-title":"Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses in postmenopausal breast cancer patients","volume":"35","author":"Bajetta","year":"1999","journal-title":"European Journal of Cancer"},{"issue":"6","key":"10.1002\/14651858.CD003370.pub2-BIB63|cit63","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/oxfordjournals.annonc.a057795","article-title":"CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer- a phase I study","volume":"1","author":"Beretta","year":"1990","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD003370.pub2-BIB64|cit64","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0277-5379(89)90032-1","article-title":"Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer","volume":"25","author":"Bruning","year":"1989","journal-title":"European Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD003370.pub2-BIB65|cit65","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/0960-0760(90)90459-X","article-title":"Second-line endocrine treatment of postmenopausal advanced breast cancer preliminary endocrine results of a 5-arm randomized phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861)","volume":"37","author":"Bruning","year":"1990","journal-title":"Journal of Steroid Biochemistry"},{"issue":"6","key":"10.1002\/14651858.CD003370.pub2-BIB66|cit66","first-page":"2229","article-title":"The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study","volume":"6","author":"Dixon","year":"2000","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD003370.pub2-BIB67|cit67","first-page":"1306","article-title":"Dose-related endocrine effects and pharmokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients","volume":"49","author":"Dowsett","year":"1989","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD003370.pub2-BIB68|cit68","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1365-2265.1990.tb00906.x","article-title":"Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients","volume":"32","author":"Dowsett","year":"1990","journal-title":"Clinical Endocrinology"},{"key":"10.1002\/14651858.CD003370.pub2-BIB69|cit69","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/bjc.1996.93","article-title":"Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer","volume":"73","author":"Bonnefoi","year":"1996","journal-title":"British Journal of Cancer"},{"issue":"10","key":"10.1002\/14651858.CD003370.pub2-BIB70|cit70","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/0959-8049(94)00281-9","article-title":"Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer","volume":"30A","author":"Dowsett","year":"1994","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD003370.pub2-BIB71|cit71","first-page":"1511","article-title":"In vivo measturement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer","volume":"1","author":"Dowsett","year":"1995","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD003370.pub2-BIB72|cit72","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/bjc.1996.531","article-title":"Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in post menopausal women with breast cancer","volume":"74","author":"Geisler","year":"1996","journal-title":"British Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD003370.pub2-BIB73|cit73","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1200\/JCO.20.3.751","article-title":"Influence of letrozole and anastrozole on totla body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomised, cross-over study","volume":"20","author":"Geisler","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003370.pub2-BIB74|cit74","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/(SICI)1097-0142(19970715)80:2<218::AID-CNCR8>3.0.CO;2-P","article-title":"A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapay for women with metastatic breast carcinoma","volume":"80","author":"Ingle","year":"1997","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD003370.pub2-BIB75|cit75","first-page":"5875","article-title":"Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer","volume":"54","author":"Johnston","year":"1994","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD003370.pub2-BIB76|cit76","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/(SICI)1097-0142(19960815)78:4<789::AID-CNCR15>3.0.CO;2-R","article-title":"Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma","volume":"78","author":"Miller","year":"1996","journal-title":"Cancer"},{"issue":"6","key":"10.1002\/14651858.CD003370.pub2-BIB77|cit77","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/00000421-199312000-00013","article-title":"Second-line hormone therapy for breast cancer. Uselessness of first-line continuation","volume":"16","author":"Pronzato","year":"1993","journal-title":"American Journal of Clinical Oncology"},{"issue":"1-3","key":"10.1002\/14651858.CD003370.pub2-BIB78|cit78","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0960-0760(92)90202-T","article-title":"Fadrozole hydrochloride, a new nontoxic aromatase inhibitor for the treatment of patients with metastatic breast cancer","volume":"43","author":"Falkson","year":"1992","journal-title":"Journal of Steroid and Biochemistry and Molecular Biology"},{"issue":"1","key":"10.1002\/14651858.CD003370.pub2-BIB79|cit79","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1200\/JCO.1992.10.1.111","article-title":"A study of fadrozole, a new aromatase inhibitor, in postmenopasual women with advanced metastatic breast cancer","volume":"10","author":"Raats","year":"1992","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD003370.pub2-BIB80|cit80","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/0959-8049(94)90168-6","article-title":"Sex hormone levels in postmenopausal women with advanced metastatic breast cancer treated with CGS 169 49A","volume":"30A","author":"Svenstrup","year":"1994","journal-title":"European Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD003370.pub2-BIB81|cit81","first-page":"188","article-title":"Treatment of advanced metastatic breast cancer with exemestane, a multicenter randomized controlled study of 195 cases","volume":"83","author":"Wang","year":"2003","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1002\/14651858.CD003370.pub2-BIB82|cit82","unstructured":"ECOG E4101 Ongoing study"},{"key":"10.1002\/14651858.CD003370.pub2-BIB83|cit83","unstructured":"Efect Phase III Ongoing study"},{"key":"10.1002\/14651858.CD003370.pub2-BIB84|cit84","unstructured":"Sofea Phase III Ongoing study"},{"key":"10.1002\/14651858.CD003370.pub2-BIB85|cit85","unstructured":"Phase III EORTC-10951 Ongoing study"},{"key":"10.1002\/14651858.CD003370.pub2-BIB86|cit86","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0140-6736(01)72307-0","article-title":"On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases","volume":"2","author":"Beatson","year":"1896","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003370.pub2-BIB87|cit87","unstructured":"Ferlay J Bray F Pisani P Parkin DM Globocan 2000: Cancer Incidence, Mortality and Prevalence Worldwide 2001"},{"issue":"3","key":"10.1002\/14651858.CD003370.pub2-BIB88|cit88","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/1097-0142(197703)39:3<1289::AID-CNCR2820390340>3.0.CO;2-F","article-title":"Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland","volume":"39","author":"Hayward","year":"1977","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD003370.pub2-BIB89|cit89","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/bmj.315.7112.863","article-title":"Recent advances in endocrine therapy of breast cancer","volume":"315","author":"Howell","year":"1997","journal-title":"British Medical Journal"},{"issue":"5","key":"10.1002\/14651858.CD003370.pub2-BIB90|cit90","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00000421-199510000-00010","article-title":"Aromatase inhibitors: current status","volume":"18","author":"Ibrahim","year":"1995","journal-title":"American Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003370.pub2-BIB91|cit91","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/0959-8049(95)00014-3","article-title":"A randomized trial comparing two doses of the new selective aromatase inhibitor anastrazole (Arimidex) with megestrol acetate in postmenopausal women with advanced breast cancer","volume":"32A","author":"Jonat","year":"1996","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD003370.pub2-BIB92|cit92","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1677\/erc.0.0030065","article-title":"Aromatase inhibitors","volume":"3","author":"Miller","year":"1996","journal-title":"Endocrine-related Cancer"},{"key":"10.1002\/14651858.CD003370.pub2-BIB93|cit93","volume-title":"Survival analysis: A Practical Approach","author":"Parmar","year":"1995"},{"key":"10.1002\/14651858.CD003370.pub2-BIB94|cit94","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/(SICI)1096-9098(199711)66:3<215::AID-JSO11>3.0.CO;2-0","article-title":"Use of aromatase inhibitors in postmenopausal women with advanced breast cancer","volume":"66","author":"Roseman","year":"1997","journal-title":"Journal of Surgical Oncology"}],"updated-by":[{"DOI":"10.1002\/14651858.cd003370.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2009,10,7]],"date-time":"2009-10-07T00:00:00Z","timestamp":1254873600000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD003370.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T17:19:36Z","timestamp":1628529576000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD003370.pub2"}},"subtitle":[],"editor":[{"given":"Judith","family":"Bliss","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2007,1,24]]},"references-count":94,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003370.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD003370.pub3","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2007,1,24]]}}}